ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 (ERADICATE Hp)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01980095|
Recruitment Status : Completed
First Posted : November 8, 2013
Results First Posted : January 10, 2017
Last Update Posted : September 24, 2019
|Condition or disease||Intervention/treatment||Phase|
|Dyspepsia Helicobacter Pylori Infection||Drug: RHB-105 Drug: Placebo||Phase 3|
This is a, randomized, double-blind, placebo-controlled study of RHB-105 in adult subjects complaining of epigastric discomfort that have been screened and found to be positive for H. pylori infection via 13C Urea Breath Test (UBT) and either fecal antigen test or CLO test.
Eligible subjects will be randomized in a ratio of 1:2 between placebo arm (n=30) and the active arm (RHB-105) (n=60). Subjects will receive study drug for 14 consecutive days. Eradication of H. pylori infection will be determined based on 13C UBT conducted between 28 to 56 days after completion of study drug therapy.
Subjects will be unblinded upon 13C UBT analysis. This will provide timely active therapy to all subjects enrolled in this study. Subjects in the placebo arm will be entitled to receive standard-of-care as prescribed by the treating physician following un-blinding.
Eradication failures (13C UBT-positive) in the active study drug arm will undergo upper endoscopy with sampling for culture and sensitivity testing (to rifabutin, amoxicillin, clarithromycin, and metronidazole). Culture and sensitivity directed therapy as prescribed by the treating physician will be offered to these subjects.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||119 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients|
|Study Start Date :||November 2013|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||August 2015|
RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.
The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:
Subjects will take study drug every 8 hours with food for 14 consecutive days.
Placebo Comparator: Placebo
Capsules that look like the RHB-105 product but contain no active ingredient.
Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
- The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing [ Time Frame: 28-56 days after completion of treatment ]Modified intent-to-treat (mITT) population analyzed included all participants whok received at least 1 dose of study drug and underwent a 13C Urea Breath Test (UBT) at Visit 4. Participants with negative test results were to be considered treatment successes. Patients who tested positive for H. pylori infection, and those with indeterminate, not assessable, or missing results were to be considered treatment failures. The statistical hypothesis that the active treatment is superior to 70% was to be tested against the alternative hypothesis that the active treatment is statistically indistinguishable or less than 70% effective using a one-sample Z-test.
- H. Pylori Eradication [ Time Frame: 28-56 days after completion of SOC treatment ]The occurrence of H. pylori eradication in Placebo and Active Drug Eradication Failure Patients treated with Standard of Care (SOC) treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01980095
|United States, California|
|Anaheim Clinical Trials, LLC|
|Anaheim, California, United States, 92801|
|Anaheim Clinical Trials|
|Anaheim, California, United States, 92801|
|Catalina Research Institute|
|Chino, California, United States, 91710|
|United States, Florida|
|Jupiter Research, Inc.|
|Jupiter, Florida, United States, 33458|
|United States, Georgia|
|Columbus Regional Research Institute|
|Columbus, Georgia, United States, 31904|
|United States, Louisiana|
|Metairie, Louisiana, United States, 70006|
|United States, Maryland|
|Investigative Clinical Research|
|Annapolis, Maryland, United States, 41401|
|MGG Group Co. Chevy Chase Clinical Research|
|Chevy Chase, Maryland, United States, 20815|
|United States, Michigan|
|Detroit Clinical Research Center|
|Farmington Hills, Michigan, United States, 48334|
|United States, Nevada|
|Office of Dr. Stephen Miller, MD|
|Las Vegas, Nevada, United States, 89144|
|United States, North Carolina|
|Peters Medical Research|
|High Point, North Carolina, United States, 27262|
|Wake Research Associates|
|Raleigh, North Carolina, United States, 27612|
|Principal Investigator:||David Y Graham, MD||Baylor College of Medicine|